Urol. praxi. 2017;18(2):69-72 | DOI: 10.36290/uro.2017.015

MRI targeted triopsy of the prostate – 1st part

MUDr. ©árka Kudláčková1, doc. MUDr. Frantiąek Zá»ura, Ph.D.1, MUDr. Zbyněk Tüdös, Ph.D.2
¹Urologická klinika Fakultní nemocnice Olomouc, ²Radiologická klinika Fakultní nemocnice Olomouc

Prostate cancer is very difficult to be identified by imaging methods. With the introduction of magnetic resonance imaging, and especially

multi-parametric evaluation techniques sensitivity and specificity of tumor imaging increased significantly. Targeted biopsy builds on

the ability of identification of tumor and the possibility of a targeted biopsy. Combination of these techniques significantly improves the

diagnosis of prostate cancer by increasing the detection of clinically significant cancer and reduces the number of unnecessary biopsies.

Keywords: prostate cancer, targeted biopsy, magnetic resonance imaging of prostate, fusion

Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kudláčková ©, Zá»ura F, Tüdös Z. MRI targeted triopsy of the prostate – 1st part. Urol. praxi. 2017;18(2):69-72. doi: 10.36290/uro.2017.015.
Download citation

References

  1. ©obrová E, Eret V, Dolejąová O, et al. Komparace multiparametrické magnetické rezonance se silou magnetického pole 3 Tesla s transrektální sonografií naváděnou biopsií prostaty. Ces Urol 2014; 18(3): 225-233.
  2. Dolejąová O, Eret V, ©obrová A, et al. Vyuľití multiparametrické magnetické rezonance a srovnání s ostatními moderními zobrazovacími metodami v předoperační diagnostice karcinomu prostaty. Ces Urol 2014; 18(4): 300-309.
  3. Ferda J, Hora M, Hes O, et al. Zobrazení prostaty na 3T MRI u nemocných se zvýąenou hladinou PSA. Ces Radiol 2012; 66(1): 9-17.
  4. Verma S, Rajesh A. A Clinically Relevant Approach to Imaging Prostate Cancer. Am J Roentgenol 2011; 196(Suppl.), S1-S10. Go to original source... Go to PubMed...
  5. Hricak H, Dooms GC, McNeal JE, et al. MR imaging of the prostate gland: normal anatomy. AJR Am J Roentgenol 1987; 148: 51-58. Go to original source... Go to PubMed...
  6. Tan CH, Hobbs BP, Wei W, Kundra V. Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol. 2015; 204: W439-448. Go to original source... Go to PubMed...
  7. Lim HK, Kim JK, Kim KA, Cho KS. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection-a multireader study. Radiology 2009; 250: 145-151. Go to original source... Go to PubMed...
  8. Kim CK, Park BK, Kim B. High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2. Am J Roentgenol 2010; 194: 1-37. Go to original source... Go to PubMed...
  9. De Cobelli F, Ravelli S, Esposito A, et al. Apparent diffusion coefficient value and ratio as noninvasive potential biomarkers to predict prostate cancer grading: comparison with prostate biopsy and radical prostatectomy specimen. American J Roentgenol 2015; 204: 550-557. Go to original source... Go to PubMed...
  10. Wysock JS, Rosenkrantz AB, Huang WC, et al. A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: The PROFUS trial. Eur Urol 2014; 66: 343-551. Go to original source... Go to PubMed...
  11. Verma S, Turkbey B, Muradyan N, et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. Am J Roentgenol 2012; 198: 1277-1288. Go to original source... Go to PubMed...
  12. Radiology ACo. PI-RADS(TM)Prostate Imaging and Reporting and Data System v2. 2015. Dostupné z: http://wwwacrorg/~/media/ACR/Documents/PDF/QualitySafety/Resources/PIRADS/PIRADSV2pdf
  13. Bjurlin MA, Mendhiratta N, Wysock JS, Taneja SS. Multiparametric MRI and targeted prostate biopsy: improvements in cancer detection, localization, and risk assessment. Cent Eur J Urol 2016; 69: 9e18. Go to original source... Go to PubMed...
  14. de Rooij M, Hamoen EH, Futterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. Am J Roentgenol 2014; 202: 343-351. Go to original source... Go to PubMed...
  15. Moore CM, Kasivisvanathan V, Eggener S, et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: Recommendations from an International Working Group. Eur Urol 2013; 64: 544-552. Go to original source... Go to PubMed...
  16. Barentsz OJ, Richenberg J, Clements R, Choyke P, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012; 22: 746-757. Go to original source... Go to PubMed...
  17. Steiger P, Thoeny H. Prostate MRI based on PI-RADS version 2: how we review and report. Cancer Imaging. 2016; 16: 9. Go to original source... Go to PubMed...
  18. Carroll PR, Parsons JK, Andriole G, et al. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014; 12: 1211-1219. Go to PubMed...
  19. Hu JC, Chang E, Natarajan S, et al. Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply? J Urol 2014; 192: 385-390. Go to original source... Go to PubMed...
  20. Kongnyuy M, George AK, Rastinehad AR, Pinto PA. Magnetic resonance imaging-ultrasound fusion-guided prostate biopsy: Review of technology, techniques, and outcomes. Curr Urol Rep 2016; 17: 32. Go to original source... Go to PubMed...
  21. Meier-Schroers M, et al. In-bore transrectal MRI-guided prostate biopsies: Are there risk factors for complications? Eur J Radiol 2016; 85(12): 2169-2173. Go to original source... Go to PubMed...
  22. Ukimura O, Desai MM, Palmer S, et al. 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol 2012; 187(3): 1080-1086. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.